Skip to main content
NAII
NASDAQ Life Sciences

NAII Q1 Sales Fall 25%, Covenant Breached; $10M Debt Now Current

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Food & Beverage Stocks · Consumer
Sentiment info
Negative
Importance info
9
Price
$0.967
Mkt Cap
$6.066M
52W Low
$0.93
52W High
$4.96
52W Position info
3.9% above low
Off High info
81% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

NAII is trading near its 52-week low of $0.93 (3.9% above the low).

Summary

NAII's fiscal Q1 sales fell 25% to $28.1M with a $2.48M net loss, and the company confirmed a covenant breach that pushes $10.0M of debt into current liabilities against $6.7M of cash.


Key Events · Earnings and Guidance · NAII

  • Q1 Sales Drop 25%

    Net sales fell to $28.1M from $37.7M, with private-label contract manufacturing down 29% to $25.6M, partly offset by a 54% rise in patent and trademark licensing revenue to $2.56M.

  • Gross Margin Collapses to 4.5%

    Gross profit fell 71% to $1.27M from $4.40M as lower volumes cut factory utilization; net loss widened to $2.48M (-$0.41/share) from $0.29M (-$0.05/share).

  • Covenant Breach Confirmed

    The fixed charge coverage ratio covenant was breached as of September 30, 2026, reclassifying $10.0M of term debt to current; total current liabilities are $39.6M against $6.7M of cash.

  • Forbearance Not Yet Secured

    Management is negotiating a forbearance letter, waiver, or amendment with Legacy Corporate Lending and does not expect to be in compliance during fiscal 2027; the lender has not indicated it will terminate the facility.


Analysis · NAII · Life Sciences

The quarter deteriorated sharply: sales fell 25% to $28.1M and gross margin compressed to 4.5%, driving a $2.48M net loss versus $0.29M a year ago. More importantly, the company confirmed it breached the fixed charge coverage ratio on its Legacy credit facility as of September 30, 2026, forcing $10.0M of term debt into current liabilities against just $6.7M of cash — and management says it does not expect to regain compliance during fiscal 2027. A going-concern warning remains in place, with the hoped-for remedies being a headquarters sale, cost cuts, and a strategic alternatives review that includes a possible sale of the company. The lender has not yet signaled it will pull the facility, but there is no forbearance or waiver in hand.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NAII was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1M. The 52-week trading range was $0.93 to $4.96. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NAII - Latest Insights

NAII
Nov 13, 2026, 4:30 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.9666
Real-time Price: $0.9666 info
Change: $0 (0%) info
Market Cap: $6.066M info
NAII
Sep 28, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.70
Real-time Price: $0.9666 info
Change: -$0.7334 (-43%) info
Market Cap: $6.066M info
NAII
Sep 28, 2026, 4:16 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.70
Real-time Price: $0.9666 info
Change: -$0.7334 (-43%) info
Market Cap: $6.066M info
NAII
May 19, 2026, 6:03 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.59
Real-time Price: $0.9666 info
Change: -$1.62 (-63%) info
Market Cap: $6.066M info
NAII
May 01, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.72
Real-time Price: $0.9666 info
Change: -$1.75 (-64%) info
Market Cap: $6.066M info